220.670 -

+2.000 (+0.91%)
Range 218.000 - 221.266   (1.50%)
Open 218.200
Previous Close 218.670
Bid Price 220.510
Bid Volume 6
Ask Price 220.770
Ask Volume 50
Volume 812,569
Value 115,714,262
Remark -
Delayed prices. Updated at 29 Jan 2026 23:29.
Data powered by
View All Events

About AbbVie

AbbVie Inc. (AbbVie) is a research-based pharmaceuticals company. The Company discovers, develops, and commercializes advanced therapies. AbbVie's portfolio of products include a line of adult and pediatric pharmaceuticals, which includes HUMIRA, metabolics/hormones products, virology products, endocrinology products, dyslipidemia products and other products. AbbVie products are used to treat rheumatoid arthritis, psoriasis, Crohn's disease, human immunodeficiency virus (HIV), cystic fibrosis complications, low testosterone, thyroid disease, Parkinson's disease and complications associated with chronic kidney disease, among other indications. In October 2012, AbbVie initiated a comprehensive Phase III program for hepatitis C virus (HCV) genotype one.

There are 30 followers

Followers
9
Followers
2
Followers
1
Followers
0
Followers
2
Followers
1
Followers
0
Followers
2
Followers
2
Followers
1
Followers
1
Followers
0
Followers
0
Followers
6
Followers
3
Followers
0
Part-time Trader | Growth Investor
Followers
5
Followers
0
Followers
0
Followers
3
Followers
20
Followers
8
Followers
0
Followers
0
Followers
0
Followers
0
Followers
0
Followers
0
Followers
0
Followers
0